Beam Therapeutics (BEAM) News Today $29.01 +2.16 (+8.04%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | markets.businessinsider.comState Street Corp Increases Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)State Street Corp raised its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 12.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 3,929,557 shares of the company's stock after purchasing an additional 437,402 shares during the perioDecember 17, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short InterestBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 10,680,000 shares, a drop of 10.8% from the November 15th total of 11,970,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 10.4 days.December 15, 2024 | marketbeat.comBeam Benefits triples revenue over three years, among fastest-growing U.S. tech companiesDecember 13, 2024 | bizjournals.comResearch Analysts Offer Predictions for BEAM FY2024 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, December 10th. Cantor Fitzgerald analyst R. Bienkowski expects that thDecember 12, 2024 | marketbeat.comCantor Fitzgerald Upgrades Beam Therapeutics (NASDAQ:BEAM) to "Hold"December 12, 2024 | americanbankingnews.comWhy Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short SellersDecember 11, 2024 | finance.yahoo.comBeam Therapeutics (NASDAQ:BEAM) Raised to Hold at Cantor FitzgeraldCantor Fitzgerald raised shares of Beam Therapeutics to a "hold" rating in a report on Tuesday.December 11, 2024 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Earns "Outperform" Rating from WedbushDecember 11, 2024 | americanbankingnews.comPromising Pipeline Developments and Market Potential Drive Buy Rating for Beam TherapeuticsDecember 10, 2024 | markets.businessinsider.comBeam Therapeutics: Strong Buy Rating Backed by Promising BEAM-101 Clinical Data in Sickle Cell DiseaseDecember 10, 2024 | markets.businessinsider.comPromising Early Data and Innovative Approaches Lead to Buy Rating for Beam TherapeuticsDecember 9, 2024 | markets.businessinsider.comBeam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingDecember 8, 2024 | globenewswire.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Charles Schwab Investment Management Inc. raised its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 6.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 629,492 shares of the compDecember 8, 2024 | marketbeat.comBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingDecember 7, 2024 | globenewswire.com20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 20,800 shares of the company's stock, valued at approximately $510,000. SeverDecember 7, 2024 | marketbeat.comBeam Therapeutics Names Sravan K. Emany as CFODecember 6, 2024 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Shares Up 8.6% - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.6% - Here's What HappenedDecember 6, 2024 | marketbeat.comBeam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerDecember 6, 2024 | globenewswire.comBeam Therapeutics Strengthens Board with Pharma VeteranDecember 5, 2024 | markets.businessinsider.comRedmile Group LLC Lowers Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Redmile Group LLC trimmed its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 5.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,611,013 shares of the company's stock after selling 92,048 shaDecember 5, 2024 | marketbeat.comErste Asset Management GmbH Purchases New Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Erste Asset Management GmbH acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,700 shares of the company's stock, valued at approximately $544,000. Other large iDecember 5, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Stock Position Reduced by Fmr LLCFmr LLC cut its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 4.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,211,517 shares of the company's stock after selling 196,178 shares during the period. FmrDecember 5, 2024 | marketbeat.comBeam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderDecember 4, 2024 | globenewswire.comWalleye Capital LLC Buys 22,664 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Walleye Capital LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 21.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,588 shares of the company's stock after buying an additionDecember 3, 2024 | marketbeat.comIntech Investment Management LLC Invests $512,000 in Beam Therapeutics Inc. (NASDAQ:BEAM)Intech Investment Management LLC purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 20,892 shares of the company's stock, valuedDecember 2, 2024 | marketbeat.comBellevue Group AG Acquires 100,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Bellevue Group AG raised its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,518,121 shares of the company's stock after purchasing anDecember 1, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, seven have assNovember 30, 2024 | marketbeat.comAlgert Global LLC Has $1.07 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Algert Global LLC grew its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 282.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,523 shares of the company's stock after purchasing an additionalNovember 29, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Stake Boosted by Quest Partners LLCQuest Partners LLC grew its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 410.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,193 shares of the company's stock after purchasing an additionaNovember 21, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short InterestBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 12,310,000 shares, an increase of 10.3% from the October 15th total of 11,160,000 shares. Based on an average daily trading volume, of 890,600 shares, the short-interest ratio is currently 13.8 days.November 16, 2024 | marketbeat.comBeam TherapeuticsNovember 15, 2024 | forbes.comBeam Therapeutics management to meet virtually with Cantor FitzgeraldNovember 15, 2024 | markets.businessinsider.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Acquired by Sumitomo Mitsui Trust Group Inc.Sumitomo Mitsui Trust Group Inc. lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 59.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,552,829 shares of the company's stock after acquiNovember 15, 2024 | marketbeat.comBaillie Gifford & Co. Has $8.76 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Baillie Gifford & Co. lowered its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 42.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 357,698 shares of the company's stock after selling 265,942 shares during the period. Baillie GNovember 13, 2024 | marketbeat.comBeam Therapeutics participates in a conference call with JPMorganNovember 13, 2024 | markets.businessinsider.comBeam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNovember 12, 2024 | globenewswire.comFroedtert, Medical College on pace to be first to offer proton therapy in WisconsinNovember 11, 2024 | msn.comResearch Analysts Issue Forecasts for BEAM FY2024 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for Beam Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($4.43) perNovember 11, 2024 | marketbeat.comGiuseppe Ciaramella Sells 51,110 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockNovember 9, 2024 | insidertrades.comBeam Therapeutics Inc. (NASDAQ:BEAM) President Sells $1,347,259.60 in StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) President Giuseppe Ciaramella sold 51,110 shares of Beam Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $26.36, for a total transaction of $1,347,259.60. Following the completion of the transaction, the president now owns 109,150 shares in the company, valued at approximately $2,877,194. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.November 8, 2024 | marketbeat.comFY2024 EPS Estimate for Beam Therapeutics Lowered by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts thaNovember 8, 2024 | marketbeat.comARK Investment Management LLC Sells 1,095,040 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)ARK Investment Management LLC cut its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 14.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,531,099 shares of the company's stock after sellingNovember 8, 2024 | marketbeat.comBeam Therapeutics upgraded to Outperform from Market Perform at LeerinkNovember 7, 2024 | finance.yahoo.comBeam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A WatchNovember 7, 2024 | seekingalpha.comBeam Therapeutics' (BEAM) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Beam Therapeutics in a research report on Thursday.November 7, 2024 | marketbeat.comWedbush Cuts Earnings Estimates for Beam TherapeuticsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Wedbush dropped their FY2024 earnings per share (EPS) estimates for shares of Beam Therapeutics in a research report issued on Tuesday, November 5th. Wedbush analyst D. Nierengarten now forecasts that the company wNovember 7, 2024 | marketbeat.comWilliam Blair Has Negative Estimate for BEAM FY2024 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair reduced their FY2024 earnings per share estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, November 5th. William Blair analyst S. Corwin now anticipates that the company will earn ($4.56) per shareNovember 7, 2024 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Upgraded by Leerink Partnrs to Strong-Buy RatingLeerink Partnrs raised shares of Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday.November 7, 2024 | marketbeat.comLeerink Partners Upgrades Beam Therapeutics (BEAM)November 7, 2024 | msn.com Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼0.970.60▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼36▲BEAM Articles Average Week Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGEN News RVMD News HALO News KRYS News ACLX News ADMA News IMVT News SRRK News CRSP News DNLI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAM Stock Alerts